Selective sensor peptides for fast, high-throughput kinase tests in Alzheimer's and related dementias
Official title: Selective Sensor Peptides for High-throughput, Kinetic Biomarker Assays of Kinase Activity in Neurodegeneration and Related Disorders
Funded at Assayquant Technologies, INC. · NIH-11410177 · Data updated 2026-11-12
A new sensor technology is being developed to measure kinase activity quickly and accurately, which could help understand and treat Alzheimer's disease and related dementias.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Assayquant Technologies, INC. NIH-funded |
| Lab location | 1 site (Marlborough, United States) |
| Project start | September 22, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,312,010 |
| NIH project number | 1R44AG102290-01 |
| Project ID | NIH-11410177 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with Alzheimer's disease or related dementias may benefit from downstream advances in diagnostics and therapeutics enabled by improved kinase assays.
✕Less likely to help
This grant focuses on assay development and may not directly involve patient participation.
What this research studies
This project aims to improve how scientists measure kinase activity, a key process in many diseases including Alzheimer's and related dementias. It uses a specialized sensor peptide that lights up when a kinase acts, allowing fast and high-throughput testing. The work focuses on making better tools for drug development and disease understanding, potentially speeding up discovery of effective therapies. It will be conducted at AssayQuant Technologies and involves collaboration to validate and scale the PhosphoSens platform for neurodegenerative disease research.
Why it matters
Potential benefit: If successful, patients could benefit from faster development of targeted therapies for Alzheimer's and related dementias.
How similar studies have gone: Previous kinase assay platforms exist, but this project aims to address their limitations with a single, high-throughput solution.
Where this research is happening
-
Assayquant Technologies, INC.
Marlborough, United States Active
Researchers
- Principal investigator: Schaefer, Erik Michael — Assayquant Technologies, INC.
- Study coordinator: Schaefer, Erik Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.